🔎 Trials Near Me

መነሻ › በርኪት ሊምፎማ › ሚሺጋን

በሚሺጋን ለበርኪት ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች

ለበርኪት ሊምፎማ የሚደረጉ 10 ጥናቶች በሚሺጋን ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በሚሺጋን ውስጥ ያሉ ከተሞች

Official study text (English)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • C S Mott Children's Hospital, Ann Arbor
  • Children's Hospital of Michigan, Detroit
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
366 Days – 46 Years · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • እና 22 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 39 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • እና 20 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • C S Mott Children's Hospital, Ann Arbor
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • Bronson Methodist Hospital, Kalamazoo
ተሳታዮችን በመፈለግ ላይደረጃ 2
365 Days · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06317662

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Corewell Health ( Site 1001), Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
6 Months – 25 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • C S Mott Children's Hospital, Ann Arbor
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • Bronson Methodist Hospital, Kalamazoo
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ1 እስከ 30 · ሁሉም ጾታዎች · የተሻሻለው በ1 ሴፕቴ 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • C S Mott Children's Hospital, Ann Arbor
  • Children's Hospital of Michigan, Detroit
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
365 Days – 25 Years · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • C.S. Mott University of Michigan, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ7 እስከ 25 · ሁሉም ጾታዎች · የተሻሻለው በ19 ኦገስ 2026 · NCT05082519

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

  • University of Michigan Rogel Cancer Center, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ጁላይ 2026 · NCT07532525

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ1 እስከ 25 · ሁሉም ጾታዎች · የተሻሻለው በ4 ሜይ 2025 · NCT03509961

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።